Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human CDK4 Anticorps:
anti-Mouse (Murine) CDK4 Anticorps:
anti-Rat (Rattus) CDK4 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal CDK4 Primary Antibody pour WB - ABIN4886533
Li, Xu, Chu, Gao, Wang, Nie, Yang, Lv: Molecular mechanism of inhibitory effects of CD59 gene on atherosclerosis in ApoE (-/-) mice. dans Immunology letters 2013
Show all 9 Pubmed References
Human Polyclonal CDK4 Primary Antibody pour IHC (p), WB - ABIN3043745
Ren, Huang, Xu, Yang, Yang, Hu: Isoflavone lupiwighteone induces cytotoxic, apoptotic, and antiangiogenic activities in DU-145 prostate cancer cells. dans Anti-cancer drugs 2015
Show all 9 Pubmed References
Human Polyclonal CDK4 Primary Antibody pour WB - ABIN3042691
Zhou, Lu, Liu, Guo, Liu, Zhou, Yang, Mi, Xu: Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo. dans Current cancer drug targets 2015
Show all 9 Pubmed References
Human Monoclonal CDK4 Primary Antibody pour ICC, WB - ABIN3043633
Cai, Xu, Zhang: Bone marrow stromal cells induce cell cycle arrest in reactive astrocytes in vitro. dans Neuroscience letters 2012
Show all 9 Pubmed References
Human Polyclonal CDK4 Primary Antibody pour IF (p), IHC (p) - ABIN671166
Zhou, Liu, Cai, Liu, Jiang, Wang: Protective effects of ginsenoside Rg1 on aging Sca?1+ hematopoietic cells. dans Molecular medicine reports 2015
Show all 2 Pubmed References
Cow (Bovine) Polyclonal CDK4 Primary Antibody pour ICC, IF - ABIN441316
Huang, Kao, Toh, Lin, Chou, Hu, Lu, Liou, Chao, Hour, Pu: UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity. dans Biochemical pharmacology 2011
Rat (Rattus) Polyclonal CDK4 Primary Antibody pour WB - ABIN1881714
Cho, Phillips, Khan, Weaver: Cloning of the rat cyclin-dependent kinase 4 cDNA: implication in proliferation-dependent expression in rat tissues. dans Biochemical and biophysical research communications 1993
Human Polyclonal CDK4 Primary Antibody pour FACS, IF - ABIN391751
Mori, Yang, Kawamata, Miller, Mizoguchi, Koeffler: Absence of R24C mutation of the CDK4 gene in leukemias and solid tumors. dans International journal of hematology 2003
Show all 3 Pubmed References
Human Monoclonal CDK4 Primary Antibody pour ICC, IF - ABIN267545
Brookes, Gagrica, Sanij, Rowe, Gregory, Hara, Peters: Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence. dans Cell cycle (Georgetown, Tex.) 2015
Human Polyclonal CDK4 Primary Antibody pour IHC (p), IHC - ABIN250624
Kim, Song, Park, Byun, Song, Kim, Kim, Hong: Primary mesenchymal tumors of the pancreas: single-center experience over 16 years. dans Pancreas 2014
Expression of cells a mutant CDK4 (CDK4(R24C)) in beta-cells enhanced beta-cell replication. CDK4(R24C) also dampened compensatory beta-cell neogenesis in larvae and improved glucose tolerance in adult zebrafish.
while mTOR (Montrer FRAP1 Anticorps) inhibitors restore endocrine sensitivity, CDK4/6 inhibitors may favor the emergence of estrogen receptor 1 (ESR1 (Montrer ESR1 Anticorps)) mutations resulting in ligand-independent activity of the receptor
Inhibition of CDK4/6 is potentially a highly effective strategy for the treatment of SHH (Montrer SHH Anticorps) and MYC (Montrer MYC Anticorps)-amplified group 3 medulloblastoma.
SOX12 (Montrer SOX12 Anticorps) can increase the expression of CDK4 and IGF2BP1 (Montrer IGF2BP1 Anticorps), which confer malignant phenotypes to Hepatocellular Carcinoma.
Study showed that CDK4 and BCAS2 (Montrer BCAS2 Anticorps) may be target genes of miR (Montrer MLXIP Anticorps)-486 and levels of CDK4 and BCAS2 (Montrer BCAS2 Anticorps) were both significantly higher in the esophageal cancer tissues and cell lines than levels in the normal tissues and cells.
Results suggest that dysregulation and activation of the cell cycle proteins CDK4/CDK6 (Montrer CDK6 Anticorps)-CCND1 (Montrer CCND1 Anticorps)-phospho-RB1 (Montrer RB1 Anticorps) axis is associated with higher proliferative index in neuroendocrine tumors (NETs).
blocking CDK4 activity efficiently eliminated both normal and chemotherapy-resistant cancer cells in triple negative breast cancers, highlighting CDK4 as a promising novel therapeutic target for these aggressive breast tumors.
Amplification of gene CDK4 is associated with lung adenocarcinoma.
PD-L1 (Montrer CD274 Anticorps) protein abundance is regulated by cyclin D-CDK4 and the cullin 3 (Montrer CUL3 Anticorps)-SPOP (Montrer SPOP Anticorps) E3 ligase via proteasome-mediated degradation
Ongoing trials of doublet and triplet targeted therapies containing ribociclib seek to identify optimal CDK4/6-based targeted combination regimens for various tumor types and advance the field of precision therapeutics in oncology
Transfection of cells with ClC-3 (Montrer CLCN3 Anticorps) siRNA decreased the expression of cyclin D1 (Montrer CCND1 Anticorps), cyclin dependent kinase 4 and 6, and increased the expression of cyclin dependent kinase (Montrer CDK1 Anticorps) inhibitors (CDKIs), p21 (Montrer CDKN1A Anticorps) and p27 (Montrer PAK2 Anticorps). Pretreatments of cells with p21 (Montrer CDKN1A Anticorps) and p27 (Montrer PAK2 Anticorps) siRNAs depleted the inhibitory effects of ClC-3 (Montrer CLCN3 Anticorps) siRNA on the expression of CDK4 and CDK6 (Montrer CDK6 Anticorps), but not on that of cyclin D1 (Montrer CCND1 Anticorps)
The in vitro cultivation of cumulus cells was associated with cell proliferation and that Cx43 (Montrer GJA1 Anticorps) and Cdk4 gene expression was upregulated after in vitro cultivation, resulting in significantly higher protein levels.
These results indicate that p18 (Montrer CDKN2C Anticorps) blocks reprogramming by targeting Cdk4/6-mediated cell cycle regulation.
Activation of cdk4 triggers NAFLD (Montrer TSC2 Anticorps).
This novel mechanism explains how CDK4 promotes anabolism by blocking catabolic processes (FAO) that are activated by AMPK (Montrer PRKAA1 Anticorps).
PD 0332991 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), prevents radiation-induced lethal intestinal injury in mice. Treating mice with PD or a structurally distinct CDK4/6 inhibitor prior to radiation blocked proliferation and crypt apoptosis and improved crypt regeneration.
The results demonstrate a unique CDK4-mediated mitochondrial communication that allows cells to sense environmental genotoxic stress and boost mitochondrial homeostasis by enhancing phosphorylation and activation of MnSOD (Montrer SOD2 Anticorps).
a crucial role of RXRa in suppression of UVB-induced melanomas in the context of driver mutations such as activated CDK4(R24C/R24C) or oncogenic NRAS(Q61K) and altered expression of p53 and PTEN
Our data indicate that Cdk2 (Montrer CDK2 Anticorps) and Cdk4 play important overlapping roles in homeostatic and stress hematopoiesis, which need to be considered when using broad-spectrum cyclin-dependent kinase (Montrer CDK1 Anticorps) inhibitors for cancer therapy.
CDK4 is a critical downstream target of MEN1-dependent tumor suppression and is required for tumorigenic proliferation in the pituitary and pancreatic islet, whereas CDK2 (Montrer CDK2 Anticorps) is dispensable for tumorigenesis in these neuroendocrine cell types.
Cdk4 and Cdk6 (Montrer CDK6 Anticorps) cooperate in hematopoietic tumor development and suggest a role for Cdk6 (Montrer CDK6 Anticorps) in sequestering INK4 proteins away from Cdk4.
CCND1 mRNA expression is increased by FGF9 in bovine theca cells and granulosa cells.
The results indicate that the precise regulation of neuronal Cdk4 activity is important to limit mitochondrial reactive oxygen species production and prevent neurodegeneration.
CDK4 activity regulates mitobiogenesis by the activation of NRF-1 (Montrer NRF1 Anticorps) and consequent induction of Tfam (Montrer TFAM Anticorps) and mitochondrial ribossomal transcription.
Delg and cyclin D/Cdk4 have roles in nutritional control of mitochondrial biogenesis in the Drosophila adipose tissue
Cyclin D-cdk4 is not a master regulator of cell multiplication in Drosophila embryos
mRpL12 (Montrer MRPL12 Anticorps) is required for CycD/Cdk4-induced cell growth
Our data suggest that the growth-specific function of CycD/Cdk4 is conserved from arthropods to mammals.
The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported.
cell division protein kinase 4
, cyclin dependent kinase 4
, serine/threonine kinase
, Cell division protein kinase 4
, Cyclin-dependent kinase 4/6
, cyclin-dependent kinase 4
, protein kinase-like 53C